Trademark Overview
On Wednesday, March 19, 2025, a trademark application was filed for OLIGOCREATOR with the United States Patent and Trademark Office. The USPTO has given the OLIGOCREATOR trademark a serial number of 79431050. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Tuesday, October 28, 2025. This trademark is owned by Secarna Pharmaceuticals GmbH & Co. KG. The OLIGOCREATOR trademark is filed in the Computer & Software Services & Scientific Services, Medical & Beauty Services & Agricultural Services, Personal, and Legal & Social Services categories with the following description:
Scientific research services in the field of biochemistry [excluding the field of cell culture products], nucleic acids and bioinformatics, in particular molecular biology techniques, especially antisense techniques; design of pharmaceutical active ingredients by means of the aforementioned processes and techniques, including the use of bioinformatics techniques; development of pharmaceutical products by means of the aforementioned processes and techniques, including the use of bioinformatics techniques, including the performance of associated testing and diagnostic procedures; bioinformatic services for the pharmaceutical and biotechnological industry; services for evaluating the efficacy and safety of pharmaceutical products.
Consultancy services to third parties in the field of biochemistry and nucleic acids and bioinformatics, including antisense technology, in relation to the development of pharmaceutical products; consultancy services to third parties in relation to the evaluation of safety and efficacy of pharmaceuticals.
Licensing of industrial property rights arising from the activities of a scientific research organisation in the field of biochemistry [excluding the field of cell culture products], nucleic acids and bioinformatics, in particular molecular biology working techniques, especially antisense technology as well as from the activities of designing active pharmaceutical ingredients by means of the aforementioned processes and techniques, including the use of bioinformatics techniques, from the development of pharmaceutical products by means of the aforementioned processes and techniques, including the use of bioinformatics techniques, including the performance of associated testing and diagnostic procedures, also from the information technology services for the pharmaceutical and biotechnological industry and from the services for evaluating the efficacy and safety of pharmaceutical products.
